(Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

By Twesha Dikshit and Ragini Mathur (Reuters) -European shares closed flat on Wednesday, surrendering early session gains, as ...

After weeks of working with U.S. officials to try to avoid hefty tariffs on Swiss goods, negotiators from Switzerland got ...

Oregon passed a new law this year requiring drug manufacturers to sell more of their medications at a discount.

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

Novartis AG NOVN -0.38% launched a lottery-style program to provide doses of its pricey gene therapy free of charge, drawing criticism from patient groups that called it an inappropriate way to ...

Novartis AG thinks its best bet for testing two new Alzheimer’s drugs is on people who don’t actually have Alzheimer’s. The Swiss drug giant is looking for people whose genes put them at ...

Avidity Biosciences ( NASDAQ: RNA) quickly soared 20% after a report that Novartis ( NYSE: NVS) made a takeover approach for the rare-disease maker.